HBV感染者耐药基因突变与肝细胞癌的相关性分析

庞婷; 邢卉春

doi:10.3969/j.issn.1001-5256.2017.01.017

HBV感染者耐药基因突变与肝细胞癌的相关性分析

DOI: 10.3969/j.issn.1001-5256.2017.01.017

庞婷,
邢卉春

1. 首都医科大学附属北京地坛医院肝病中心
2. 首都医科大学附属北京世纪坛医院感染科

基金项目:

“十二五”国家科技重大专项(2014ZX10005001)；国家自然科学基金(81201160)；北京市中医药科技项目(JJ2014-25)；

详细信息

中图分类号: R512.62;R735.7
计量
- 文章访问数: 2254
- HTML全文浏览量: 33
- PDF下载量: 419
- 被引次数: 0
出版历程
- 收稿日期: 2016-08-08
- 出版日期: 2017-01-20

Correlation between drug-resistance gene mutations and hepatocellular carcinoma in patients with hepatitis B virus infection

Liver Research Center,Beijing Ditan Hospital,Capital Medical University

Research funding:

摘要

摘要:
目的探讨HBV耐药基因突变与肝细胞癌（HCC）的相关性。方法收集2013年1月1日-12月31日在北京地坛医院进行HBV耐药基因突变检测,且为核苷和核苷酸类药物经治,但HBV DNA仍可检测到的患者的临床资料。对其进行随访,以出现HCC为临床结局。分析HBV感染者耐药基因突变与HCC发生的相关性。计数资料组间比较采用χ2检验,计量资料组间比较采用t检验,并采用log-rank检验比较组间HCC发生率的差异。结果共有227例患者纳入研究,其中HBV耐药基因突变检测结果中未检测到耐药基因突变者占45.37%（103/227）,检测到耐药基因突变者占54.63%（124/227）。HBV耐药基因突变组与未突变组的HBV DNA载量分别为（5.19±1.60）log10IU/ml、（5.44±1.75）log10IU/ml,两组差异无统计学意义（t=-1.134,P=0.258）。HBV耐药基因突变组与未突变组中肝硬化患者的比例分别为24.19%（30/124）、16.50%（17/103）,两组差异亦无统计学意义（χ2=2.026,P=0.155）...
- 肝炎病毒,乙型 /
- 癌,肝细胞 /
- 突变 /
- 抗药性
Abstract:
Objective To investigate the correlation between hepatitis B virus( HBV) drug- resistance gene mutations and hepatocellular carcinoma( HCC). Methods The clinical data of treatment- experienced patients,who underwent examination for HBV drug- resistance gene mutations in Beijing Ditan Hospital from January 1 to December 31,2013,and still had detectable HBV DNA after being treated with nucleos( t) ide analogues,were collected. All the patients were followed up,and the development of HCC was considered as the clinical outcome. The correlation between drug- resistance gene mutations and the development of HCC in patients with HBV infection was analyzed.The chi- square test was used for comparison of categorical between groups,the t- test was used for comparison of continuous data between two groups,and the log- rank test was used for comparison of the incidence of HCC between two groups. Results A total of 227 patients were enrolled in this study. According to the results of the detection of HBV drug- resistance gene mutations,103 patients( 103 /227,45. 37%) had no drug- resistance gene mutations and 124( 124 /227,54. 63%) had drug- resistance gene mutations. There were no significant differences between the mutation group and the non- mutation group in HBV DNA load( 5. 19 ± 1. 60 log10 IU / ml vs 5. 44 ± 1. 75log10 IU / ml,t =- 1. 134,P = 0. 258) and the percentage of patients with liver cirrhosis( 24. 19%( 30 /124) vs 16. 50%( 17 /103),χ~2=2. 026,P = 0. 155). The median follow- up was 28 months( range 4- 58 months),and the incidence of HCC was 7. 49%( 17 /227). Among the patients with HBV drug- resistance gene mutations,12( 12 /124,9. 68%) developed HCC,and among those without HBV drug- resistance gene mutations,5( 5 /103,4. 85%) developed HCC. Among the patients who developed HCC,70. 59%( 12 /17) had HBV drug- resistance gene mutations at baseline; among the patients who did not develop HCC,53. 33%( 112 /210) had HBV drug- resistance gene mutations at baseline. Conclusion The patients with poor control of HBV DNA during antiviral therapy have a comparable incidence of HCC to those not treated with antiviral therapy,with a relatively high risk of developing HCC; the treated patients with HBV drug- resistance gene mutations may have a higher risk of HCC than those without such mutations,which needs to be confirmed by the studies with a longer follow- up period and a larger sample size.
- hepatitis B virus /
- carcinoma /
- hepatocellular /
- mutation

HTML全文

参考文献(19)

[1]World Health Organization.Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[EB/OL].[2015-03]http://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/.

[2]ZHUANG H.Interpretation of expert consensus on drug resistance in treatment of chronic hepatitis B with nucleos(t)ide analogues and its management[J].J Med Res,2013,42(9):1-2.(in Chinese)庄辉.核苷(酸)类药物治疗慢性乙型肝炎耐药及其管理专家共识解读[J].医学研究杂志,2013,42(9):1-2.

[3]di MARCO V,MARZANO A,LAMPERTICO P,et al.Clinical outcome of HBe Ag-negative chronic hepatitis B in relation to virological response to lamivudine[J].Hepatology,2004,40(4):883-891.

[4]LAI MW,YEH CT.The oncogenic potential of hepatitis B virus rt A181T/surface truncation mutant[J].Antivir Ther,2008,13(7):875-879.

[5]LAI MW,HUANG SF,HSU CW,et al.Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy[J].Antivir Ther,2009,14(2):249-261.

[6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[7]Ministry of Health of the People's Republic of China.Updated standards for the diagnosis and treatment of primary liver cancer(2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.

[8]LAMONTAGNE J,MILLS C,MAO R,et al.Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system[J].Antiviral Res,2013,98(1):19-26.

[9]MESE S,ARIKAN M,CAKIRIS A,et al.Role of the line probe assay INNO-Li PA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients[J].J Gen Virol,2013,94(12):2729-2738.

[10]HONGTHANAKORN C,CHOTIYAPUTTA W,OBERHELMAN K,et al.Virological breakthrough and drug-resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice[J].Hepatology,2011,53(6):1854-1863.

[11]KEKULEAS,LAUER U,MEYER M,et al.The pre S2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator[J].Nature,1990,343(6257):457-461.

[12]RODRIGUEZ C,CHEVALIEZ S,BENSADOUN P,et al.Characterization of the dynamics of hepatitis B virus drug-resistance to adefovir by ultra-deep pyrosequencing[J].Hepatology,2013,58(3):890-901.

[13]VIETHEER PT,NETTER HJ,SOZZI T,et al.Failure of the lamivudine-resistant rt M204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion[J].J Virol,2005,79(10):6570-6573.

[14]YEH CT,CHEN T,HSU CW,et al.Emergence of the rt A181T/s W172*mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B[J].BMC cancer,2011,11:398.

[15]OU ZY,ZHANG YJ,ZHAGN R,et al.Relationship between mutation of HBV YMDD motif and pathogenesis of hepatocellular carcinoma[J].J Trop Med,2008,8(6):525-528.(in Chinese)欧志英,张耀军,张韧,等.HBV YMDD模序突变及其与肝癌发生的关系[J].热带医学杂志,2008,8(6):525-528.

[16]WANG LN,LI XF.Correlation study on hepatitis B virus YMDD variation in primary hepatic carcinoma[J].Lab Med,2012,27(12):1047-1049.(in Chinese)王丽娜,李晓斐.乙型肝炎病毒YMDD变异与原发性肝癌相关性研究[J].检验医学,2012,27(12):1047-1049.

[17]HOSAKA T,SUZUKI F,KOBAYASHI M,et al.Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants[J].Hepatol Res,2010,40(2):145-152.

[18]JUN CH,HONG HJ,CHUNG MW,et al.Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B[J].World J Gastroenterol,2013,19(40):6834-6841.

[19]LIAW YF,SUNG JJ,CHOW WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med,2004,351(15):1521-1531.

施引文献

资源附件(0)

访问统计